Christopher Molineaux's most recent trade in Aclaris Therapeutics Inc was a trade of 42,350 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 42,350 | 42,350 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 11,580 | 11,580 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 57,956 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 4,793 | 4,793 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 53,163 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 16,500 | 0 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.41 per share. | 20 Jun 2023 | 16,500 | 48,503 (0%) | 0% | 1.4 | 23,265 | Common Stock |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.52 per share. | 15 Jun 2023 | 198 | 32,003 (0%) | 0% | 1.5 | 301 | Common Stock |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 198 | 0 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 51 | 0 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.73 per share. | 15 Jun 2023 | 51 | 31,805 (0%) | 0% | 0.7 | 37 | Common Stock |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 31,754 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Christopher Molineaux | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 27,247 (0%) | 0% | - | Common Stock |